Viewing StudyNCT00388440



Ignite Creation Date: 2024-05-05 @ 5:04 PM
Last Modification Date: 2024-10-26 @ 9:28 AM
Study NCT ID: NCT00388440
Status: COMPLETED
Last Update Posted: 2016-09-20
First Post: 2006-10-13

Brief Title: Assess GSK Biologicals MMR Vaccine Priorix When Given to Healthy Children at the Age of 12 to 18 Months in Singapore
Sponsor:
Organization: GlaxoSmithKline

Study Design

Study Type: INTERVENTIONAL
Expanded Access Type Individual: None
Expanded Access Type Intermediate: None
Expanded Access Type Treatment: None
Patient Registry: None
Target Duration: None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention: None
Bio Spec Description: None
Enrollment Count: 150
Enrollment Type: ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
Name
PHASE4
Observational Models:
Time Perspective List:
Who Masked List: